natgillin/translations-raw huggingface dataset:
Following administration of a supratherapeutic dose of 10 mg linagliptin concomitantly with 40 mg of simvastatin daily for 6 days, the plasma AUC of simvastatin was increased by 34%, and the plasma Cmax by 10%. 
Nakon primjene supraterapijske doze 10 mg linagliptina istovremeno s 40 mg simvastatina dnevno u trajanju od 6 dana, AUC simvastatina u plazmi povećan je za 34%, a Cmax u plazmi za 10%.
There was no increased risk in hospitalization for heart failure which was an additional adjudicated endpoint observed compared to standard of care without linagliptin in patients with type 2 diabetes (table 4). 
Nije bilo povećanog rizika od hospitalizacije zbog zatajenja srca, što je bila dodatno procijenjena mjera ishoda promatrana u odnosu na uobičajeno liječenje bez linagliptina u bolesnika s dijabetesom tipa 2 (vidjeti tablicu 4).
Co-administration with other potent inducers of P-glycoprotein and CYP3A4, such as carbamazepine, phenobarbital and phenytoin has not been studied. 
Istovremena primjena s drugim snažnim induktorima P-glikoproteina i CYP3A4, kao što su karbamazepin, fenobarbital i fenitoin, nije ispitivana.
They have "D2/850" debossed on one side and the Boehringer Ingelheim logo debossed on the other. 
Imaju oznaku "D2/850" utisnutu na jednoj strani te logo Boehringer Ingelheima na drugoj strani.
Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. 
Neki lijekovi mogu štetno utjecati na funkciju bubrega, što može povećati rizik od laktacidoze, npr. NSAIL-ovi, uključujući selektivne inhibitore ciklooksigenaze (COX) II, ACE inhibitore, antagoniste receptora angiotenzina II i diuretike, osobito diuretike Henleove petlje.
They have "D2/1000" debossed on one side and the Boehringer Ingelheim logo debossed on the other. 
Imaju oznaku "D2/1000" utisnutu na jednoj strani te logo Boehringer Ingelheima na drugoj strani.
Gastrointestinal disorders Decreased appetite uncommon 
Poremećaji probavnog sustava Smanjeni apetit manje često
No other additive toxicity caused by the combination of linagliptin and metformin was observed at AUC exposure levels up to 2 and 23 times human exposure, respectively. 
Druga dodatna toksičnost izazvana kombinacijom linagliptina i metformina nije bila opažena pri vrijednostima AUC izloženosti do 2, odnosno 23 puta višim od izloženosti u ljudi.
A delayed time to peak serum concentrations by 2 hours was observed for metformin under fed conditions. 
Odgođeno vrijeme do postizanja vršnih koncentracija u serumu za 2 sata opaženo je pri uzimanju metformina uz hranu.
Co-administration of a high-fat meal with linagliptin prolonged the time to reach Cmax by 2 hours and lowered Cmax by 15%, but no influence on AUC 0-72h was observed. 
Istovremena primjena visokomasnog obroka s linagliptinom je produljila vrijeme do postizanja Cmax za 2 sata i smanjila Cmax za 15%, ali nije primijećen učinak na AUC0-72h.
Jentadueto is not recommended in patients with hepatic impairment due to the active substance metformin (see sections 4.3 and 5.2). 
Jentadueto se ne preporučuje u bolesnika s oštećenjem jetre zbog djelatne tvari metformina (vidjeti dijelove 4.3 i 5.2).
Hypoglycaemia (frequency very common (may affect more than 1 in 10 people)) is an identified side effect for the combination of Jentadueto plus sulphonylurea and for the combination Jentadueto plus insulin. 
Hipoglikemija (učestalost vrlo česta (mogu se javiti u više od 1 na 10 osoba)) je prepoznata kao nuspojava kombinacije Jentadueta i sulfonilureje te kombinacije Jentadueta i inzulina.
Due to the concentration dependent binding of linagliptin to DPPIV, the pharmacokinetics of linagliptin based on total exposure is not linear; indeed total plasma AUC of linagliptin increased in a less than dose-proportional manner, while unbound AUC increases in a roughly dose-proportional manner. 
Zbog vezanja linagliptina na DPP-IV, koje je ovisno o koncentraciji, farmakokinetika linagliptina temeljena na ukupnoj izloženosti nije linearna, doista, ukupni AUC linagliptina u plazmi povećao se manje od proporcionalnog s dozom, dok se nevezani AUC ugrubo povećao proporcionalno s dozom.
Some patients have experienced allergic reactions (frequency rare), which may be serious, including wheezing and shortness of breath (bronchial hyperreactivity; frequency uncommon (may affect up to 1 in 100 people)). 
Neki bolesnici su imali alergijske reakcije (učestalost rijetka) koje mogu biti teške, uključujući piskanje u plućima i kratkoću daha (bronhalna hiperreaktivnost; učestalost manje česta (mogu se javiti u do 1 na 100 osoba)).
In patients with mild moderate and severe hepatic impairment (according to the Child-Pugh classification), mean AUC and Cmax of linagliptin were similar to healthy matched controls following administration of multiple 5 mg doses of linagliptin. 
U bolesnika s blagim, umjerenim i teškim oštećenjem jetre (prema Child-Pughovoj klasifikaciji), prosječni AUC i Cmax linagliptina slični su odgovarajućim zdravim kontrolama nakon primjene višestrukih doza 5 mg linagliptina.
isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration. 
izavukonazol) može smanjiti eliminaciju metformina putem bubrega i tako dovesti do povišenja koncentracije metformina u plazmi.
(1) reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis, (2) in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilisation, 
(1) smanjenjem proizvodnje glukoze u jetri inhibicijom glukoneogeneze i glikogenolize, (2) povećanjem osjetljivosti na inzulin u mišićima i time poboljšanjem perifernog unosa i iskorištavanja glukoze, (3) i odgađanjem intestinalne apsorpcije glukoze.
• Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin. 
• induktorima OCT1 (kao što je rifampicin) može povećati gastrointestinalnu apsorpciju i djelotvornost metformina.
Stop taking Jentadueto and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma. 
Prestanite uzimati Jentadueto i odmah se obratite liječniku ili otiđite u najbližu bolnicu ako osjetite neke od simptoma laktacidoze, jer to stanje može dovesti do kome.
It does not stimulate insulin secretion and therefore does not produce hypoglycaemia. 
Ne potiče sekreciju inzulina te stoga ne dovodi do hipoglikemije.
For the entire treatment period (median time on treatment 5.9 years) the rate of patients with moderate or severe hypoglycaemia was 6.5% on linagliptin versus 30.9% on glimepiride, severe hypoglycaemia occurred in 0.3% of patients on linagliptin versus 2.2% on glimepiride. 
Tijekom ukupnog razdoblja liječenja (medijan vremena liječenja 5,9 godina) stopa bolesnika s umjerenom ili teškom hipoglikemijom iznosila je 6,5% na linagliptinu naspram 30,9% na glimepiridu, teška hipoglikemija javila se u 0,3% bolesnika na linagliptinu naspram 2,2% na glimepiridu.
OUTER CARTON AND LABEL - HDPE BOTTLE (17 AND 18 APPLICABLE ONLY FOR CARTON) 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM I UNUTARNJEM PAKIRANJU VANJSKA KUTIJA I NALJEPNICA - HDPE BOCA (TOČKE 17. I 18. PRIMJENJIVE SAMO ZA KUTIJU)
Therefore, linagliptin is not an inhibitor of OCT-mediated transport. 
Stoga, linagliptin nije inhibitor prijenosa posredovanog OCT-om.
In analyses for albuminuria progression (change from normoalbuminuria to micro- or macroalbuminuria, or from microalbuminuria to macroalbuminuria) the estimated hazard ratio was 0.86 (95% CI 0.78, 0.95) for linagliptin versus placebo. 
U analizama progresije albuminurije (promjena s normoalbuminurije na mikro- ili makroalbuminuriju, ili s mikroalbuminurije na makroalbuminuriju) ocijenjeni omjer hazarda iznosio je 0,86 (95% CI 0,78, 0,95) za linagliptin naspram placeba.
Major adverse cardiovascular events (MACE) and mortality by treatment group in the CAROLINA study 
Tablica 5 Veliki štetni kardiovaskularni događaji (engl. major adverse cardiovascular events, MACE) i mortalitet po liječenoj skupini u ispitivanju CAROLINA
Discontinuation of therapy due to adverse events was comparable in patients who received placebo and metformin to patients treated with linagliptin and metformin (3.8% and 2.9%). 
Prekid liječenja zbog štetnih događaja bio je usporediv u bolesnika koji su primali placebo i metformin u usporedbi s bolesnicima liječenim linagliptinom i metforminom (3,8% i 2,9%).
This medicine does not require any special temperature storage conditions. 
Lijek ne zahtijeva čuvanje na određenoj temperaturi.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR BLISTERS 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA ZA BLISTERE
Metformin hydrochloride is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. 
Metforminklorid je bigvanid s antihiperglikemijskim učincima koji snižava i bazalnu i postprandijalnu razinu glukoze u plazmi.
Not all pack sizes may be marketed in your country. 
Na tržištu se ne moraju nalaziti sve veličine pakiranja.
Co-administration of multiple doses of linagliptin and metformin did not meaningfully alter the pharmacokinetics of either linagliptin or metformin in healthy volunteers and patients. 
Istovremena primjena višekratnih doza linagliptina i metformina nije značajno promijenila farmakokinetiku bilo linagliptina ili metformina u zdravih dobrovoljaca i bolesnika.
Metformin is contraindicated 
Metformin je kontraindiciran.
As a result of tissue binding, the mean apparent volume of distribution at steady-state following a single 5 mg intravenous dose of linagliptin to healthy subjects is approximately 1110 litres, indicating that linagliptin extensively distributes to the tissues. 
Kao rezultat vezanja u tkivima prosječni prividni volumen distribucije u stanju dinamičke ravnoteže nakon jednostruke intravenske doze linagliptina od 5 mg primijenjene na zdravim osobama je oko 1 110 litara, što ukazuje na ekstenzivnu distribuciju linagliptina u tkivima.
Patients treated with linagliptin exhibited a significant mean decrease from baseline in body weight compared to a significant weight gain in patients administered glimepiride (-1.39 versus +1.29 kg). 
Bolesnici liječeni linagliptinom pokazali su značajno prosječno smanjenje od početne vrijednosti u tjelesnoj težini u usporedbi sa značajnim porastom težine u bolesnika koji su primali glimepirid (-1,39 u odnosu na +1,29 kg).
High overdose of metformin hydrochloride or concomitant risks may lead to lactic acidosis. 
Visoko predoziranje metforminkloridom ili istovremeni rizici mogu dovesti do laktacidoze.
Patients switching from co-administration of linagliptin and metformin For patients switching from co-administration of linagliptin and metformin, Jentadueto should be initiated at the dose of linagliptin and metformin already being taken. 
Bolesnici koji se prebacuju s istovremene primjene linagliptina i metformina Za bolesnike koji se prebacuju s istovremene primjene linagliptina i metformina, primjenu Jentadueta je potrebno početi na dozi linagliptina i metformina koja se već uzima.
Total daily dose of linagliptin is equal to 5 mg 
Ukupna dnevna doza linagliptina iznosi 5 mg
Liver, kidneys and gastrointestinal tract are the principal target organs of toxicity in mice and rats at repeat doses of linagliptin of more than 300 times the human exposure. 
Jetra, bubrezi i gastrointestinalni trakt najvažniji su ciljni organi toksičnosti kod miševa i štakora pri ponovljenim dozama linagliptina koje su preko 300 puta više nego kod izloženosti ljudi.
- bronchodilators (β-sympathomimetics) for the treatment of bronchial asthma. 
(kortikosteroidi). - bronhodilatatori (β-simpatomimetici) za liječenje bronhalne astme. - lijekovi koji sadrže alkohol.
The most frequently reported adverse reaction for linagliptin plus metformin was diarrhoea (1.6%) with a comparable rate on metformin plus placebo (2.4%). 
Najčešće prijavljena nuspojava za kombinaciju linagliptin plus metformin bila je proljev (1,6%) s usporedivom stopom kombinacije metformin plus placebo (2,4%).
Linagliptin also showed significant improvements in fasting plasma glucose (FPG) compared to placebo. 
Linagliptin je također pokazao značajna poboljšanja glukoze u plazmi natašte u usporedbi s placebom.
The study population included 2089 (35%) patients with cardiovascular disease and 1130 (19%) patients with renal impairment with an eGFR < 60ml/min/1.73m2 at baseline. 
Ispitivana populacija uključila je 2089 (35%) bolesnika s kardiovaskularnom bolešću i 1130 (19%) bolesnika s oštećenjem funkcije bubrega uz eGFR < 60 ml/min/1,73 m2 na početku ispitivanja.
Adverse reactions reported in all clinical trials with the linagliptin+metformin combination or the use of the monocomponents (linagliptin or metformin) in clinical trials or from post-marketing experience are shown below according to system organ class. 
Nuspojave prijavljene u svim kliničkim ispitivanjima s kombinacijom linagliptin+metformin ili uz primjenu pojedinačnih komponenti (linagliptina ili metformina) u kliničkim ispitivanjima ili nakon stavljanja lijeka u promet navedene su u nastavku prema klasifikaciji organskih sustava.
A NOAEL of 78 times human exposure was derived for embryo-fetal toxicity in rabbits, and for maternal toxicity the NOAEL was 2.1 times human exposure. 
NOAEL pri 78 puta većoj izloženosti od one u ljudi, dobiven je za embriofetalnu toksičnost kod kunića, a za toksičnost majke NOAEL je bio 2,1 puta viši od izloženosti kod ljudi.
Placebo Linagliptin 5 mg Once 
Placebo Linagliptin 5 mg jedanput dnevno
Cardiac function 
Funkcija srca
Based on these results and in vivo drug interaction studies, linagliptin is considered unlikely to cause interactions with other P-gp substrates. 
Na osnovi ovih rezultata kao i in vivo ispitivanja interakcija lijekova, ne smatra se da linagliptin izaziva interakcije s drugim
Sulphonylureas: 
Sulfonilureje:
Jentadueto combines two antihyperglycaemic medicinal products with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: linagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, and metformin hydrochloride, a member of the biguanide class. 
Jentadueto kombinira dva antihiperglikemijska lijeka s komplementarnim mehanizmima djelovanja kako bi se poboljšala kontrola glikemije u bolesnika s dijabetesom tipa 2: linagliptin, inhibitor dipeptidil peptidaze 4 (DPP-4), i metforminklorid, član skupine bigvanida.
Multiple daily doses of linagliptin had a minimal effect on the steady-state pharmacokinetics of simvastatin, a sensitive CYP3A4 substrate, in healthy subjects. 
Višekratne dnevne doze linagliptina imale su minimalan učinak na farmakokinetiku simvastatina u stanju dinamičke ravnoteže, osjetljivog supstrata enzima CYP3A4, u zdravih ispitanika.
* Based on lipase elevations >3xULN observed in clinical trials # Based on Linagliptin cardiovascular and renal safety study (CARMELINA), see also below Adverse reactions reported in patients who received metformin as monotherapy and that were not observed in patients receiving Jentadueto. 
* na osnovi povišenja lipaze >3xGGN opaženih u kliničkim ispitivanjima na osnovi Ispitivanja sigurnosti primjene linagliptina za kardiovaskularni sustav i bubrege (CARMELINA), vidjeti u nastavku nuspojave prijavljene u bolesnika koji su primili metformin kao monoterapiju i koje nisu bile opažene u bolesnika koji su primili Jentadueto.
Linagliptin glucose-dependently increases insulin secretion and lowers glucagon secretion thus resulting in an overall improvement in the glucose homeostasis. 
Linagliptin povećava sekreciju inzulina ovisno o glukozi i snižava sekreciju glukagona, što rezultira ukupnim poboljšanjem homeostaze glukoze.
Studies in animals have shown excretion of both metformin and linagliptin into milk in lactating rats. 
Ispitivanja na životinjama pokazala su da se i metformin i linagliptin izlučuju u mlijeko ženki štakora u laktaciji.
In clinical trials, the incidence rates of hypoglycemia were comparably low in patients taking linagliptin in combination with metformin or metformin alone. 
U kliničkim ispitivanjima, stope incidencije hipoglikemije bile su usporedivo niske u bolesnika koji su uzimali linagliptin u kombinaciji s metforminom ili metformin kao monoterapiju.
A statistically significant greater proportion of patients with a baseline HbA1c ≥7.0% and treated with linagliptin 5 mg achieved a target HbA1c of <7% compared to placebo. 
Statistički značajno veći udio bolesnika s početnom vrijednošću HbA1c ≥ 7,0% i liječenih linagliptinom 5 mg postigli su ciljnu vrijednost HbA1c < 7% u usporedbi s placebom.
Boehringer Ingelheim Ellas A.E. 5th km Paiania - Markopoulo Koropi Attiki, 194 00 
5th km Paiania - Markopoulo Koropi Attiki, 194 00
Abdominal pain very common 
Bol u abdomenu vrlo često
Maximum daily dose is 1000 mg. 
Maksimalna dnevna doza je 1000 mg.
Maximum daily dose is 3000 mg. 
Maksimalna dnevna doza je 3000 mg.
Digoxin: 
Digoksin:
If this happens you must stop taking Jentadueto and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma. 
Ako Vam se to dogodi, morate prestati uzimati lijek Jentadueto i odmah se obratiti liječniku ili otići u najbližu bolnicu, jer laktacidoza može dovesti do kome.
Intravascular administration of iodinated contrast agents may lead to contrast induced nephropathy, resulting in metformin accumulation and an increased risk of lactic acidosis. 
Intravaskularna primjena jodiranih kontrastnih sredstava može dovesti do nefropatije izazvane kontrastom, što dovodi do nakupljanja metformina i povećanja rizika od laktacidoze.
Metformin hydrochloride stimulates intracellular glycogen synthesis by acting on glycogen synthase. 
Metforminklorid potiče intracelularnu sintezu glikogena djelovanjem na glikogen sintazu.
Jentadueto is also available in plastic bottles with plastic screw cap and a silica gel desiccant. 
Jentadueto je također dostupan u plastičnim bocama s plastičnim zatvaračem na navoj i silikagelom kao sredstvom za sušenje.
Non-clinical reproduction studies did not indicate an additive teratogenic effect attributed to the coadministration of linagliptin and metformin. 
Neklinička ispitivanja utjecaja na reprodukciju nisu ukazala na dodatne teratogene učinke povezane s istovremenom primjenom linagliptina i metformina.
Linagliptin 5 mg once daily and 2.5 mg twice daily provided comparable (CI: -0.07; 0.19) significant HbA1c reductions of -0.80% (from baseline 7.98%), and -0.74% (from baseline 7.96%) compared to placebo. 
Linagliptin 5 mg jedanput dnevno i 2,5 mg dvaput dnevno dali su usporediva (CI: -0,07; 0,19) značajna smanjenja HbA1c od -0,80% (od početne vrijednosti 7,98%), i -0,74% (od početne vrijednosti 7,96%) u usporedbi s placebom.
Jentadueto should not be used during pregnancy. 
Jentadueto se ne smije primjenjivati u trudnoći.
The NOAEL for fertility, early embryonic development and teratogenicity in rats was set at > 900 times the human exposure. 
NOAEL za plodnost, rani razvoj embrija i teratogenost kod štakora postavljen je na doze > 900 puta više od izloženosti kod ljudi.
Bioequivalence studies in healthy subjects demonstrated that the Jentadueto (linagliptin/metformin hydrochloride) combination tablets are bioequivalent to co-administration of linagliptin and metformin hydrochloride as individual tablets. 
Ispitivanja bioekvivalencije na zdravim ispitanicima pokazala su da su Jentadueto (linagliptin/metforminklorid) kombinirane tablete bioekvivalentne istovremenoj primjeni linagliptina i metforminklorida u obliku odvojenih tableta.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). 
Ispitivanja na životinjama ne ukazuju na izravan ili neizravan štetan učinak na reprodukciju (vidjeti dio 5.3).
No teratogenic effects were observed in rabbits at > 1,000 times human exposure. 
Nisu primijećeni teratogeni učinci u kunića pri dozama > 1000 puta višima od izloženosti kod ljudi.
The safety of linagliptin 2.5 mg twice daily (or its bioequivalent of 5 mg once daily) in combination with metformin has been evaluated in over 6800 patients with type 2 diabetes mellitus. 
Sigurnost linagliptina 2,5 mg dvaput dnevno (ili njegovog bioekvivalenta od 5 mg jedanput dnevno) u kombinaciji s metforminom ocjenjivana je na više od 6800 bolesnika s dijabetes melitusom tipa 2.
Steady-state predictions for AUC of linagliptin in patients with ESRD indicated comparable exposure to that of patients with moderate or severe renal impairment. 
Predviđanja za AUC linagliptina u stanju dinamičke ravnoteže kod bolesnika s ESRD-om (bolešću bubrega u završnoj fazi) ukazala su na usporedivu izloženost s onom kod bolesnika s umjerenim ili teškim oštećenjem bubrega.
• in patients already being treated with the combination of linagliptin and metformin as separate tablets. 
• u bolesnika koji se već liječe kombinacijom linagliptina i metformina u obliku zasebnih tableta.
The observed incidence of hypoglycaemia in patients treated with linagliptin was similar to placebo. 
Primijećena incidencija hipoglikemije kod bolesnika liječenih linagliptinom bila je slična placebu.
Erythema very rare 
Eritem vrlo rijetko
An embryofetal development study in pregnant rats did not indicate a teratogenic effect attributed to the co-administration of linagliptin and metformin at AUC exposure levels up to 4 and 30 times human exposure, respectively. 
Ispitivanje embrio-fetalnog razvoja u skotnih štakora nije ukazalo na teratogene učinke pripisane istovremenoj primjeni linagliptina i metformina pri vrijednostima AUC izloženosti do 4, odnosno 30 puta većoj od izloženosti u ljudi.
Pack sizes of 14, 60 and 180 film-coated tablets. 
Veličine pakiranja od 14, 60 i 180 filmom obloženih tableta.
When linagliptin and metformin were administered in combination with insulin, hypoglycaemia was the most frequently reported adverse event, but occurred at comparable rate when placebo and metformin were combined with insulin (linagliptin plus metformin plus insulin 29.5% and 30.9% in the placebo plus metformin plus insulin group) with a low rate of severe (requiring assistance) episodes (1.5% and 0.9%). 
Kada su se linagliptin i metformin primijenili u kombinaciji s inzulinom, hipoglikemija je bila najčešće prijavljen štetni događaj, ali se ona pojavila u usporedivoj stopi kada su se placebo i metformin kombinirali s inzulinom (linagliptin plus metformin plus inzulin 29,5% i 30,9% u skupini placebo plus metformin plus inzulin) s niskom stopom teških (koje su zahtijevale pomoć) epizoda (1,5% i 0,9%).
Symptoms of lactic acidosis are non-specific such as feeling or being very sick, vomiting, stomach ache with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in breathing. 
Simptomi laktacidoze su nespecifični kao što su mučnina ili jako povraćanje, bol u trbuhu uz grčeve mišića, općeniti osjećaj lošeg stanja uz težak umor i otežano disanje.
Change in clinical status of patients with previously controlled type 2 diabetes As Jentadueto contains metformin, a patient with previously well controlled type 2 diabetes on Jentadueto who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. 
S obzirom da Jentadueto sadrži metformin, bolesnik s prethodno dobro kontroliranim dijabetesom tipa 2 na Jentaduetu koji razvije laboratorijske abnormalnosti ili kliničku bolest (naročito nejasno i loše definiranu bolest), mora se hitno ocijeniti u pogledu dokaza ketoacidoze ili laktacidoze.
The pharmacokinetics of linagliptin was generally similar in healthy subjects and in patients with type 2 diabetes. 
Farmakokinetika linagliptina bila je općenito slična kod zdravih osoba i kod bolesnika s dijabetesom tipa 2.